Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05021757 · ClinicalTrials.gov registry record
Disrupt CAD III Post-Approval Study (PAS)
A clinical trial, sponsored by Shockwave Medical.
- Completed
- Registry status
- 1,212
- Enrollment target
NCT05021757: Completed study, sponsored by Shockwave Medical.
NCT05021757 is a clinical trial that has completed, run by Shockwave Medical. The registered enrollment target is 1,212 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05021757 has completed, sponsored by Shockwave Medical.
- COMPLETED
- Registry status
- 1,212 participants
- Enrollment target
Study Summary
The study design is a prospective, multicenter, observational, single-arm post-approval study using data collected in the National Cardiovascular Data Registry (NCDR®) CathPCI Registry®.
Interventions
- DEVICE Shockwave C2 Coronary IVL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,212 participants |
| Start Date | 2021-03-10 |
| Est. Completion | 2022-03-31 |
What the finished NCT05021757 record still lists
NCT05021757 is an observational study that tracks outcomes without assigning an intervention. Its 1,212 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Shockwave C2 Coronary IVL is the first listed.
NCT05021757 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05021757 about?
NCT05021757 is a clinical study titled "Disrupt CAD III Post-Approval Study (PAS)". The study design is a prospective, multicenter, observational, single-arm post-approval study using data collected in the National Cardiovascular Data Registry (NCDR®) CathPCI Registry®.
What is the current status of trial NCT05021757?
This trial is currently completed. The enrollment target is 1,212 participants. The study started on 2021-03-10. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT05021757?
The interventions under investigation include: Shockwave C2 Coronary IVL (DEVICE).
Who is sponsoring clinical trial NCT05021757?
This trial is sponsored by Shockwave Medical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT05827016 · 1,216 participants · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- NCT06143956 · 1,217 participants · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI